NRX Pharmaceuticals, Inc. - Common Stock NRXP 深 沪
等待开盘 11-19 09:30:00 美东时间
2.28
+0.170
+8.06%
华盛通- 最 高2.295
- 今 开2.16
- 成交量 44.57万股
- 最 低 2.0408
- 昨 收 2.11
- 总市值 6406.25万
- 52周最高 6.01
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.15
- 委 比 0.50%
- 总股本 2809.76万
- 历史最高 769.90
- 量 比 0.77
- 振 幅 12.05%
- 历史最低 1.58
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 17, 2025
Companies Reporting Before The Bell • So-Young Intl (NASDAQ:SY) is projected to...
11-17 19:11
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NRx Pharmaceuticals announced updates on its drug development and financial results for Q3 2025. The Company refiled its ANDA for preservative-free ketamine (KETAFREE™), received FDA support, and anticipates a Q2 2026 approval. HOPE Therapeutics expanded its Florida network to three facilities, with plans for six by year-end, offering neuroplastic drugs, TMS, and hyperbaric therapy for suicidal depression and PTSD. NRx secured funding through Jul...
11-17 13:03
Earnings Outlook For NRX Pharmaceuticals
NRX Pharmaceuticals (NASDAQ:NRXP) is gearing up to announce its quarterly earni...
11-14 23:02
HOPE Therapeutics Launches First-in-Florida Deployment Of Ampa ONE-D Protocol, Achieving Single-Day Remission Rates Up To 72% In Treatment-Resistant Depression
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.HOPE is one of the first Ampa deployments nationwide and is now
11-10 21:14
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $46 to $47.
10-30 19:16
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Nurix Therapeutics announced the pricing of an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, expected to raise $250 million. The offering includes participation from new and existing investors and is set to close on October 23, 2025. Proceeds will be used for clinical development, pipeline expansion, and general corporate purposes. Nurix is a biopharmaceutical company focused on targeted protein degrad...
10-22 11:20
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
HOPE Therapeutics acquired Cohen and Associates, a leading interventional psychiatry clinic specializing in treatments like TMS and ketamine. Dr. Rebecca Cohen, a renowned TMS expert, has joined HOPE as Medical Director, overseeing clinical standards in Florida. The acquisition is expected to boost HOPE's revenue and EBITDA, with plans for rapid expansion in Western Florida and Palm Beach. Cohen, LLC was founded by Dr. Cohen in 2014 as one of the...
10-20 12:03
NRx Pharmaceuticals (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
Austin, Texas, United States, October 17th, 2025, FinanceWire The company has r...
10-18 00:30
